SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
BioMed News Bytes: Arena (NASDAQ: ARNA), ImmunoCellular (OTC: IMUC.OB), YM Bio (AMEX: YMI)
ARNA
|
|
|
Shares of Arena Pharma (NASDAQ: ARNA) (AH $6.58, +34% at 5:10pm ET on heavy, above-average volume for the day) are surging on news that the Company will <font> conduct a conference call Friday 18-September at 8am ET </font> to discuss the BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) Phase 3 study (its second pivotal Phase 3 study for this compound) results for its experimental weight loss drug lorcaserin and expects to submit a NDA for FDA approval by year-end based on guidance provided in late March, which is outlined below. <> ...
|
FDA Calendar: Five Weight Loss Trades
ARNA
|
|
|
<> Below are five small/micro-cap companies from the <font> BioMedReports.com FDA Calendar </font> with late-stage drugs or medical devices in development for prescription weight loss. Nearly two-thirds or 65% of U.S. population is classified as obese or overweight with a three-fold increase in adolescent obesity rates over the past three decades. Obesity is the second leading cause of preventable deaths behind smoking and weight loss is proven to decrease mortality while also improving blood sugar control in diabetics. Over one-third (35%) of people in the U.S. have a lifetime of devel...
|
Extreme FDA Calendar Trades: 18 Stocks Under $5
ARNA
|
|
|
<> Below are extreme trades among companies with stock prices under $5 from the <font> BioMedReports.com FDA Calendar </font> , which includes 232 entries as of 7/3/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissio...
|
Arena Pharmaceuticals Inc
ARNA
|
|
|
Last trade signal was SELL
at 2009-May-13
Price: $2.72
<table width="600"> <tbody> <tr> <td> <table> <tbody> <tr> <td> </td> <td> for ARNA </td> <td> </td> </tr> <...
|
FDA Calendar Updates: MITI, KERX, GSK, DYAX, ARNA, PGNX
ARNA
|
|
|
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of about 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-s...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on ARNA |
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Arena Pharmaceuticals Inc
- Answers.com
